Loading...
On September 15, 2005, GlaxoSmithKline (GSK) announced that it had halted clinical trials of the CCR5 entry inhibitor, aplaviroc (GW873140), in HIV-infected, treatment-naive patients because of concerns about severe hepatotoxicity. Two phase IIb, dose-ranging trials of aplaviroc were being conducted in North America and Europe. In the first, 147 HIV-infected, treatment-naive patients were randomized to receive Combivir (AZT/3TC) plus either efavirenz or aplaviroc (600 mg twice daily or 800 mg twice daily). In the second trial, 195 HIV-infected, treatment-naive patients were randomized to receive lopinavir/ritonavir (Kaletra) plus either Combivir or aplaviroc (200 mg twice daily, 400 mg twice daily, or 800 mg once daily). In the two trials c…